星状神经节阻滞治疗创伤后应激障碍症状的随机临床试验
这项多中心、盲法、假操作对照随机临床试验纳入113名现役军人,按2:1随机接受右侧星状神经节阻滞(SGB)或假操作,于第0周和第2周各治疗一次。
要点
- 2次间隔2周的右侧SGB可降低现役军人PTSD症状严重度。
- 基线症状为轻中度且随访仅8周,结果外推受限。
核心结论
- 在伴有PTSD症状(达临床阈值及亚阈值)的现役军人中,间隔2周的2次SGB治疗在8周内有效降低CAPS-5总症状严重度评分。
- 作者认为SGB作为PTSD辅助治疗值得进一步开展试验。
研究设计与样本
- 多中心、盲法、假操作对照随机临床试验,SGB与假操作按2:1随机分组。
- 2016年5月至2018年3月在美国3个陆军跨学科疼痛管理中心开展。
- 仅实施操作的医生和操作护士知晓分组,参与者与评估者均不知情。
- 纳入精神药物剂量稳定且筛查时PCL-C评分≥32的现役军人。
- 共筛查190人,113人符合条件并随机分组(SGB组74人,假操作组39人),108人完成研究。
主要发现
- 基线CAPS-5平均(SD)评分SGB组为37.6(11.2)、假操作组为39.8(14.4),量表范围0-80。
- 113名参与者中91人(80.0%)符合CAPS-5的PTSD诊断标准。
关键数值与推荐
- 主要结局指标为基线至8周CAPS-5总症状严重度评分平均改善≥10分,并按中心和基线总症状严重度评分校正(预先计划)。
- 随机分组样本中100名为男性、13名为女性,平均(SD)年龄37.3(6.7)岁。
- 113名随机参与者中108人(95.6%)完成研究。
临床怎么用
- 对伴有PTSD症状且精神药物剂量稳定的现役军人,可考虑将间隔2周的2次右侧SGB作为辅助治疗选项。
- 应用时需注意本研究基线症状为轻中度、随访仅8周,不能据此推断长期疗效。
- 既往接受过SGB、特定精神疾病或物质使用障碍、中重度创伤性脑损伤或近2个月有自杀意念者被排除,此类人群不适用本结果。
局限性
- 基线PTSD症状严重度为轻中度,限制结果外推。
- 随访时间仅8周,无法评估长期疗效。
- 研究人群为现役军人,向其他人群推广需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: This is the first multisite, randomized clinical trial of stellate ganglion block (SGB) outcomes on posttraumatic stress disorder (PTSD) symptoms. OBJECTIVE: To determine whether paired SGB treatments at 0 and 2 weeks would result in improvement in mean Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total symptom severity scores from baseline to 8 weeks. DESIGN, SETTING, AND PARTICIPANTS: This multisite, blinded, sham-procedure, randomized clinical trial used a 2:1 SGB:sham ratio and was conducted from May 2016 through March 2018 in 3 US Army Interdisciplinary Pain Management Centers. Only physicians performing the procedures and the procedure nurses were aware of the intervention (but not the participants or assessors); their interactions with the participants were scripted and limited to the 2 interventions. Active-duty service members on stable psychotropic medication dosages who had a PTSD Checklist-Civilian Version (PCL-C) score of 32 or more at screening were included. Key exclusion criteria included a prior SGB treatment, selected psychiatric disorders or substance use disorders, moderate or severe traumatic brain injury, or suicidal ideation in the prior 2 months. INTERVENTIONS: Paired right-sided SGB or sham procedures at weeks 0 and 2. MAIN OUTCOMES AND MEASURES: Improvement of 10 or more points on mean CAPS-5 total symptom severity scores from baseline to 8 weeks, adjusted for site and baseline total symptom severity scores (planned a priori). RESULTS: Of 190 screened individuals, 113 (59.5%; 100 male and 13 female participants; mean [SD] age, 37.3 [6.7] years) were eligible and randomized (74 to SGB and 39 to sham treatment), and 108 (95.6% of 113) completed the study. Baseline characteristics were similar in the SGB and sham treatment groups, with mean (SD) CAPS-5 scores of 37.6 (11.2) and 39.8 (14.4), respectively (on a scale of 0-80); 91 (80.0%) met CAPS-5 PTSD criteria. In an intent-to-treat analysis, adjusted mean total symptom severity score change was -12.6 points (95% CI, -15.5 to -9.7 points) for the group receiving SGB treatments, compared with -6.1 points (95% CI, -9.8 to -2.3 points) for those receiving sham treatment (P = .01). CONCLUSIONS AND RELEVANCE: In this trial of active-duty service members with PTSD symptoms (at a clinical threshold and subthreshold), 2 SGB treatments 2 weeks apart were effective in reducing CAPS-5 total symptom severity scores over 8 weeks. The mild-moderate baseline level of PTSD symptom severity and short follow-up time limit the generalizability of these findings, but the study suggests that SGB merits further trials as a PTSD treatment adjunct. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03077919.
引用
- Rae Olmsted KL, Bartoszek M, Mulvaney S, et al. Effect of Stellate Ganglion Block Treatment on Posttraumatic Stress Disorder Symptoms: A Randomized Clinical Trial. JAMA Psychiatry. 2020. PMID: 31693083. doi:10.1001/jamapsychiatry.2019.3474
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。